Changes in US Oncology Drug Reimbursement: Medicare Sets the Pace

The SAGE Handbook of Healthcare ◽

10.4135/9781848605985.n2 ◽

2013 ◽

pp. 20-40

Keyword(s):

Drug Reimbursement ◽

Download Full-text

Health‐related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan‐Canadian Oncology Drug Review

Cancer ◽

10.1002/cncr.32455 ◽

2019 ◽

Vol 126 (1) ◽

pp. 148-155 ◽

Author(s):

Adam J. N. Raymakers ◽

Dean A. Regier ◽

Stuart J. Peacock

Keyword(s):

Quality Of Life ◽

Health Related Quality ◽

Drug Reimbursement ◽

Oncology Drug ◽

Related Quality ◽

Health Related ◽

Download Full-text

PCN143 COST-EFFECTIVENESS OBSERVATIONS AND ONCOLOGY DRUG REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE JOINT ONCOLOGY DRUG REVIEW

Value in Health ◽

10.1016/s1098-3015(10)72231-2 ◽

2010 ◽

Vol 13 (3) ◽

pp. A51 ◽

Author(s):

CC Ciapanna ◽

S Yunger ◽

D Shum ◽

D Milliken ◽

CJ Longo ◽

...

Keyword(s):

Cost Effectiveness ◽

Drug Reimbursement ◽

Oncology Drug ◽

Download Full-text

The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017

PharmacoEconomics ◽

10.1007/s40273-018-0610-0 ◽

2018 ◽

Vol 36 (4) ◽

pp. 467-475 ◽

Author(s):

Chris Skedgel ◽

Dominika Wranik ◽

Min Hu

Keyword(s):

Cancer Drug ◽

Revealed Preferences ◽

Relative Importance ◽

Drug Reimbursement ◽

Oncology Drug ◽

Patient Values ◽

Download Full-text

Can Quality-Adjusted Life Year Avoidance Help in Oncology Drug Reimbursement Decisions?

Journal of Oncology Practice ◽

10.1200/jop.0711501 ◽

2008 ◽

Vol 4 (1) ◽

pp. 8-8

Author(s):

John E. Calfee

Keyword(s):

Quality Adjusted Life Year ◽

Drug Reimbursement ◽

Oncology Drug ◽

Quality Adjusted Life

Download Full-text

FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

Case Medical Research ◽

10.31525/cmr-1a454b4 ◽

2019 ◽

Author(s):

Keyword(s):

Download Full-text

FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

Case Medical Research ◽

10.31525/fda2-ucm626710.htm ◽

2018 ◽

Author(s):

Keyword(s):

Download Full-text

Immunophenotyping, RNAseq, microbiota analysis of syngeneic mouse models treated with immune checkpoint inhibitors to support biomarker and immune-oncology drug discovery

European Journal of Cancer ◽

10.1016/s0959-8049(16)32919-7 ◽

2016 ◽

Vol 69 ◽

pp. S108

Author(s):

L. Zhang ◽

M. Qiao ◽

J. Zhang ◽

S. Guo ◽

W. Qian ◽

...

Keyword(s):

Drug Discovery ◽

Mouse Models ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Syngeneic Mouse ◽

Oncology Drug ◽

Microbiota Analysis ◽

Immune Oncology

Download Full-text

Next generation oncology drug development: opportunities and challenges

Nature Reviews Clinical Oncology ◽

10.1038/nrclinonc.2009.38 ◽

2009 ◽

Vol 6 (5) ◽

pp. 259-265 ◽

Author(s):

Martin E. Gutierrez ◽

Shivaani Kummar ◽

Giuseppe Giaccone

Keyword(s):

Drug Development ◽

Next Generation ◽

Oncology Drug ◽

Oncology Drug Development

Download Full-text

Website information on oncology drug benefits vs risks

Reactions Weekly ◽

10.1007/s40278-016-21377-5 ◽

2016 ◽

Vol 1620 (1) ◽

pp. 11-11

Keyword(s):

Drug Benefits ◽

Download Full-text

China's oncology drug market on the rise

The Lancet Oncology ◽

10.1016/s1470-2045(21)00176-5 ◽

2021 ◽

Vol 22 (5) ◽

pp. 586-587

Author(s):

Chris McCall

Keyword(s):

Drug Market ◽

Download Full-text